Article Information
- Received June 20, 2006
- Revision received April 25, 2007
- Accepted April 25, 2007
- First published June 27, 2007.
- Version of record published June 27, 2007.
Author Information
- Lora K. Heisler1,
- Nina Pronchuk2,
- Katsunori Nonogaki3,4,
- Ligang Zhou1,
- Jacob Raber5,
- Loraine Tung1,
- Giles S. H. Yeo1,
- Stephen O'Rahilly1,
- William F. Colmers2,
- Joel K. Elmquist6, and
- Laurence H. Tecott3
- 1Department of Clinical Biochemistry, Addenbrooke's Hospital and the University of Cambridge, Cambridge CB2 2QR, United Kingdom,
- 2Department of Pharmacology, University of Alberta, Edmonton, Alberta, Canada T6G 2H7,
- 3Department of Psychiatry and Center for Neurobiology and Psychiatry, University of California at San Francisco, San Francisco, California 94117,
- 4Division of Molecular Metabolism and Diabetes, Tohoku University Graduate School of Medicine, Miyagi 980-8575, Japan,
- 5Departments of Behavioral Neuroscience and Neurology, Division of Neuroscience, Oregon National Primate Research Center, Oregon Health & Science University, Portland, Oregon 97239, and
- 6Departments of Internal Medicine and Pharmacology, The University of Texas Southwestern Medical Center, Dallas, Texas 75390
- Correspondence should be addressed to either of the following: Dr. Joel K. Elmquist, Departments of Internal Medicine and Pharmacology, Division of Hypothalamic Research, The University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9051, joel.elmquist{at}UTSouthwestern.edu; or Dr. Lora K. Heisler, Department of Clinical Biochemistry, Addenbrooke's Hospital, Hills Road, University of Cambridge, Cambridge CB2 2QQ, UK, lkh30{at}medschl.cam.ac.uk
Author contributions
Disclosures
- Received June 20, 2006.
- Revision received April 25, 2007.
- Accepted April 25, 2007.
-
This work was supported by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Grant R01DK65171, the National Alliance for Research on Schizophrenia and Depression, and the Bank of America–Giannini Foundation (L.K.H.); Scientific Research (C2) and Takeda Research Foundation (K.N.); the Wellcome Trust (G.S.H.Y., S.O'R.); the Medical Research Council (L.T., S.O'R.); National Institute of Mental Health (NIMH) Grant R01MH061583 and NIDDK Grant P01DK056116 (J.K.E.); NIMH Grant R01MH61624 and the EJLB Foundation (L.H.T.); National Institutes of Health Grant R01AG20904 and Ellison Medical Foundation Grant AG-NS-0201 (J.R.); and Canadian Institutes of Health Research Grant MT 10520 and Merck Research Laboratories (W.F.C.).
- Correspondence should be addressed to either of the following: Dr. Joel K. Elmquist, Departments of Internal Medicine and Pharmacology, Division of Hypothalamic Research, The University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390-9051, joel.elmquist{at}UTSouthwestern.edu; or Dr. Lora K. Heisler, Department of Clinical Biochemistry, Addenbrooke's Hospital, Hills Road, University of Cambridge, Cambridge CB2 2QQ, UK, lkh30{at}medschl.cam.ac.uk
Online Impact